drugset / Trial / NCT00647764

Safety Study Of SNX-5422 To Treat Solid Tumor Cancers And Lymphomas

NCT00647764

Non-randomizedSingle-groupOpen-labelTreatment

Summary

Hsp90 is a chemical in the body that is involved in promotion of cancer. SNX-5422 is an experimental drug that blocks Hsp90. It is being evaluated for safety and efficacy in patients with cancer.

Timeline

Start
2008-03
Primary completion
2010-09
Completion
2010-09

Drugs

EvaluationDrugModalityDoseRoute
Subject SNX-5422 Small molecule Oral

Indications